DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-679]

Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT 30 DAYS AFTER PUBLICATION IN THE FEDERAL REGISTER].

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on June 22, 2020, Galephar Pharmaceutical Research, Inc., 100 Carr 198

Industrial Park, Juncos, Puerto Rico 00777-3873, applied to be registered as an importer of the following basic class(es) of a controlled substance:

Controlled Substance	Drug Code	Schedule
Hydromorphone	9150	II

The company plans to import the listed controlled substance in finished dosage form for analytical purpose only.

William T. McDermott,
Assistant Administrator.

[FR Doc. 2020-14614 Filed: 7/7/2020 8:45 am; Publication Date: 7/8/2020]